Antithrombotic therapy of unstable angina and non-Q-wave myocardial infarction

International Journal of Cardiology

Volumn 68, Issue SUPPL. 1, 1999, Pages

  Ferrario, Maurizio ^a   Merlini, Piera Angelica ^b   Lucreziotti, Stefano ^a   Poli, Arnaldo ^a   Cantù, Francesco ^a   Gobbi, Giuseppe ^a   Bramucci, Ezio ^a   Mussini, Antonio ^a   Ardissino, Diego ^a  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^b OSPEDALE NIGUARDA CA GRANDA   (Italy)

Author keywords

Anticoagulants; Antiplatelets; Non Q wave myocardial infarction; Unstable angina

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; LOW MOLECULAR WEIGHT HEPARIN;

ACUTE PHASE RESPONSE; ANGIOGRAPHY; ANGIOSCOPY; ARTICLE; DRUG EFFECT; DRUG EFFICACY; HEART INFARCTION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; Q WAVE; THROMBOCYTE AGGREGATION; THROMBOGENESIS; UNSTABLE ANGINA PECTORIS;

ANGINA, UNSTABLE; ANTIBODIES, MONOCLONAL; ANTICOAGULANTS; ASPIRIN; FIBRINOLYTIC AGENTS; HEPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; TREATMENT OUTCOME;

EID: 0033541529     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-5273(98)00293-9     Document Type: Article

References (55)

1. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes (1). N Engl J Med 1992; 326: 242-250.
2. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes (2). N Engl J Med 1992; 326: 310-318.
3. Davies MJ, Thomas AC. Plaque fissuring - The cause of acute myocardial infarction, sudden ischaemic death, and crescendo angina. Br Heart J 1985; 53:363-373.
4. DeWood MA, Spores J, Notske R et al. Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N Engl J Med 1980; 303:897-902.
5. Mizuno K, Satomura K, Miyamoto A. et al. Angioscopic evaluation of coronary artery thrombi in acute coronary syndromes. N Engl J Med 1992; 326: 287-291.
6. Baumgartner HR. The role of blood flow in platelet adhesion, fibrin deposition, and formation of mural thrombi. Microvasc Res 1973; 5:167-179
7. Badimon L, Badimon JJ. Mechanisms of arterial thrombosis in nonparallel streamlines: platelet thrombi grow on the apex of stenotic severely injured vessel wall: experimental study in the pig model. J Clin Invest 1989; 84: 1134-1144.
8. Johnson EA, Mulloy B. The molecular-weight range of mucosal heparin preparations. Carbohydr Res 1976; 51:119-127.
9. Rosenberg RD, Bauer KA. The heparin-antithrombin system: a natural anticoagulant mechanism. In: Colman RW, Hirsh J, Marder VJ, Salzman EW, editors. Hemostasis and Thrombosis: Basic Principles and Clinical Practice. 3rd ed. Philadelphia, Pa: JB Lippincott, 1994:837-60.
10. Salzman EW, Rosenberg RD, Smith MH, Lindon JN, Favreau L. Effect of heparin and heparin fractions on platelet aggregation. J Clin Invest 1980; 65: 64-73.
11. Williams DO, Kirby MG, McPherson K, Phear DN. Anticoagulant treatment of unstable angina. Br J Chin Pract 1986; 40: 114-116.
12. Zwerner PL, Gore JM, Corrao JM et al. Heparin in the treatment of unstable angina: a randomized prospective trial. Circulation (abstract) 1987; 76(Suppl IV): IV-180.
13. Telford AM, Wilson C. Trial of heparin versus atenolol in prevention of myocardial infarction in intermediate coronary syndrome. Lancet 1981; 1:1225-1228.
14. Théroux P, Ouimet H, McCans J, et al. Aspirin, heparin, or both to treat acute unstable angina. N Engl J Med 1988; 319: 1105-1111.
15. Théroux P, Waters D, Qiu S, McCans J, de Guise P, Juneau M. Aspirin versus heparin to prevent myocardial infarction during the acute phase of unstable angina. Circulation 1993; 88 (part 1): 2045-2048.
16. Neri Serneri GG, Gensini GF, Poggesi L, et al. Effect of heparin, aspirin, or alteplase in reduction of myocardial ischaemia in refractory unstable angina. Lancet 1990; 335:615-618.
17. The RISC Group. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary disease. Lancet 1990; 336: 827-30.
18. Théroux P, Waters D, Lam J, Juneau M, McCans J. Reactivation of unstable angina after the discontinuation of heparin. N Engl J Med 1992; 327: 141-145.
19. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIb Investigators. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. N Engl J Med 1996; 335: 775-82.
20. Weitz JI, Hudoba M, Massel D, Maraganore J, Hirsh J. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest 1990; 86: 385-391.
21. Walker FJ, Esmon CT. The effects of phospholipid and factor Va on the inhibition of factor Xa by antithrombin III. Biochem Biophys Res Commun 1979; 90: 641-647.
22. Lane DA, Pejler G, Flynn AM, Thompson EA, Lindahl U. Neutralization of heparin-related saccharides by histidine-rich glycoprotein and platelet factor 4. J Biol Chem 1986; 261: 3980-3986.
23. Blajchman MA, Young E, Ofosu FA. Effects of unfractionated heparin, dermatan sulfate and low molecular weight heparin on vessel wall permeability in rabbits. Ann NY Acad Sci 1989; 556: 245-254.
24. Lewis HD Jr, Davis JW, Archibald DG, et al. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina: results of a Veterans Administration Cooperative Study. N Engl J Med 1983; 309: 396-403.
25. Cairns JA, Gent M, Singer J, et al. Aspirin, sulfinpyrazone, or both in unstable angina: results of a Canadian multicenter trial. N Engl J Med 1985; 313: 1369-1375.
26. Antiplatelet Trialists' Collaboration. Collaborative overview of randomized trials of antiplatelet therapy. I: prevention of death, myocardial infarction and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J 1994; 308: 81-106.
27. Grotemeyer KH, Scharafinski HW, Husstedt IW. Two-year follow-up of aspirin responders and aspirin non responders. A pilot-trial including 180 post-stroke patients. Throm Res 1993; 71: 397-403.
28. Hennekens CH, Eberlein K, for the Physicians' Health Study Research Group. A randomized trial of aspirin and b-carotene among US physicians. Prey Med 1985; 14: 165-168.
29. Roderick PJ, Wilkes HC, Meade TW. The gastrointestinal toxicity of aspirin: an overview of randomized controlled trials. Br J Clin Pharmacol 1993; 35: 219-226.
30. Hirsh J, Levine MN. Low molecular weight heparin. Blood 1992, 79(No 1): 1-17.
31. Samama MM, Bara L, Gerotziafas GT. Mechanisms for the antithrombotic activity in man of low molecular weight heparins (LMWHs). Haemostasis 1994; 24: 105-117.
32. Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995; 332: 1330-1335.
33. Fragmin During Instability in Coronary Artery Disease (FRISC) Study Group. Low-molecular weight heparin during instability in coronary artery disease. Lancet 1996; 347: 561-568.
34. Gurfinkel EP, Manos EJ, Mejail RI, et al. Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia. J Am Coll Cardiol 1995; 26: 313-318.
35. Klein WK, Buchwald A, Hillis SE, et al. Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Fragmin in unstable coronary artery disease (FRIC). Circulation 1997; 96: 61-68.
36. Cohen M, Demers C, Gurfinkel EP, et al. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. N Engl J Med 1997; 337: 447-452.
37. The Thrombolysis In Myocardial Infarction (TIMI) 1 1A trial Investigators. Dose-ranging trial of enoxaparin for unstable angina: results of TIMI 11A. J Am Coll Cardiol 1997; 29: 1474-1482.
38. Antman EM, Braunwald F. Trials and tribulations of thrombin. Eur Heart J 1996; 17: 971-973.
39. Lefcovits J, Topol EJ. Direct thrombin inhibitors in cardiovascular medicine. Circulation 1994; 90: 1522-1536.
40. Scharf M, Engels J, Tripier D. Primary structures of new "isohirudins". FEBS Lett. 1989; 255: 105-110.
41. Maraganore JM, Bourdon P, Jablonski J, Ramachandran KL. Design and characterization of hirulogs: a novel class of bivalent peptide inhibitors of thrombin. Biochemistry 1990; 29: 7095-7101.
42. Powers JC, Kam CM. Synthetic substrates and inhibitors of thrombin. In: Berliner U, editor. Thrombin: structure and function. New York, NY: Plenum Press, 1992:117-158.
43. Topol EJ, Fuster V, Harrington RA, et al. Recombinant hirudin for unstable angina pectoris. A multicenter, randomized angiographic trial. Circulation 1994; 89: 1557-1566.
44. Lidon R, Théroux P, Juneau M, Adelman B, Maraganore J. Initial experience with a direct antithrombin, hirulog, in unstable angina: anticoagulant, antithrombotic and clinical effects. Circulation 1993, 88: 1495-1501.
45. Fuchs J, Cannon CP, and the TIMI 7 Investigators. Hirulog in the treatment of unstable angina. Results of the thrombin inhibition in myocardial ischemia (TIMI) 7 trial. Circulation 1995; 92: 727-33.
46. Gold HK, Torres FW, Garabedian HD, et al. Evidence for a rebound coagulation phenomenon after cessation of a 4-hour infusion of a specific thrombin inhibitor in patients with unstable angina pectoris. J Am Coll Cardiol 1993; 21: 1039-1047.
47. Antman EM, for the TIMI-9B Investigators. Hirudin in acute myocardial infarction Thrombolysis and thrombin inhibition in Myocardial Infarction (TIMI) 9B trial. Circulation 1996, 94: 911-921.
48. Poncz M, Eisman R, Heidenreich R, et al. Structure of the platelet membrane glycoprotein lib. J Biol Chem 1987; 262: 8476-8482.
49. Gralnick FIR, Williams SB, Coller BS. Fibrinogen competes with von Willebrand factor for binding to the glycoprotein IIb/IIIa complex when platelets are stimulated with thrombin. Blood 1984; 64: 797-800.
50. Simoons ML, Jan de Boer M, van den Brand MJBM, et al. Randomized trial of a GPIIb/IIIa platelet receptor blocker in refractory unstable angina. Circulation 1994; 89: 596-603.
51. The CAPTURE Investigators. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE trial. Lancet 1997; 349: 1429-1435.
52. Théroux P, Kouz S, Roy L, et al. Platelet membrane receptor glycoprotein IIb/IIIa antagonism in unstable angina. The Canadian Lamifiban Study. Circulation 1996; 94: 899-905.
53. The Platelet Receptor Inhibition in Isehemic Syndrome Management (PRISM) Study Investigators. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N Engl J Med 388:1498-1505.
54. The Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. Inhibition of the platelet glycoprotein lib/IIIa receptor with tirofiban in unstable angina - and non-Q-wave myocardial infarction. N Engl J Med 338:1488-1497.
55. The PARAGON Investigators. An international, randomized, controlled trial of lamifiban, a platelet glycoprotein IIb/IIIa inhibitor or heparin or both in unstable angina. Submitted for publication.